The oncology specialist will advance its lead drug candidate into Phase 2 trials with the proceeds of the $60m round, which featured existing investor Purdue Pharmaceuticals.

Max Planck Institute and Brown University team up on new company looking to create 3D digital avatars.

Intel previously invested in BASIS Science, a producer of wearable health trackers, through its series B round in October 2013.

Eli Lilly and Company has invested an undisclosed amount of funding in Audion Therapeutics, a Netherlands company developing a treatment for sensorineural hearing loss, as part of a series A round.

Baxter Ventures, the corporate venturing unit behind US pharmaceutical company Baxter International, has invested $50.7m in a series B round of funding for Covagen, a developer of therapeutic medicines for people suffering from inflammatory diseases, such as rheumatoid arthritis.

Corning has led a $34m round for NinePoint Medical, a manufacturer of in-vivo pathology devices, bringing its overall funding to $67m.

The Amunix-backed biopharmaceutical company could close its initial public offering at almost $145m, and will invest the proceeds in developing its lead drug candidate.